Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 23, 2018--
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an
early access program in Europe for rucaparib for treatment and as
maintenance therapy in recurrent ovarian cancer. The program will be
overseen and implemented by Caligor Coghlan, which specializes in early
access to medicines.
The program, to be known as the Rucaparib Access Program (RAP), will
enable participation fro...
Rubraca offers a new option for women with advanced BRCA mutant
ovarian cancer with platinum-sensitive, relapsed or progressive
disease, who are unable to tolerate further platinum based chemotherapy
First PARP inhibitor recommended for treatment indication in the EU
European Commission (EC) formal approval is anticipated Q2 2018
Once approved by the EC, Clovis plans to file a variation to the
• Claims to be issued cover all commercial dosage strengths of Rubraca®
• This will be the 10th Orange Book-listed
patent for Rubraca
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 8, 2018--
Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has
received a Notice of Allowance from the United States Patent and
Trademark Office in United States Patent Application 14/828,065 with
claims directed to high dosage strength ruc...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.